Skip to main content
Premium Trial:

Request an Annual Quote

Sequenta Secures Rights to iRepertoire IP for Immune Cell Sequencing

NEW YORK (GenomeWeb News) – Sequenta has gained the exclusive rights to iRepertoire's IP related to methods of immune cell sequencing for minimal residual disease testing, the two companies said today.

iRepertoire's IP complements Sequenta's existing MRD patents and strengthens its ability to provide new products and new features, they said. Sequenta in February began offering its ClonoSight test through its CLIA laboratory. The test is based on the South San Francisco, Calif.-based company's LymphoSight technology, which sequences unique DNA signatures present in immune cells, allowing researchers to track malignant sub-populations at levels as low as one cell per million white blood cells.

Last month, Sequenta said it raised $20 million in a Series C financing round.

iRepertoire, headquartered in Huntsville, Ala., markets tools for immune profiling. Through its R10k program it also discovers and develops immune repertoire signatures.

"This deal underscores the value of immune cell profiling and of our platform and will enable us to move our business forward in other areas," iRepertoire CEO Jian Han said in a statement.

Financial and other terms of the deal were not disclosed.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.